All In MedTech

Device Trial Radar · NCT07336433

SMART-IC-Pilot Study

EFS Study of the Renal Nerve Mapping/Selective Renal Denervation (msRDN) System in the Absence of Antihypertensive Medications: A Prospective, Multicentre, Single-Arm Exploratory Trial

Last checked: Nov 20, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Jan 1, 2026

Primary completion

Jun 30, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
SyMap Medical (Suzhou), Ltd.Not on our public-company list
Sponsor type
Industry
First posted
Jan 13, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This small-scale, proof-of-concept pilot study aims to obtain preliminary evidence of msRDN procedural safety, feasibility, and short-term efficacy in patients with hypertension without medication therapy, to adequately plan an appropriate pivotal study.

Conditions

  • Hypertensive Disease

Interventions

  • The SymPioneer G2 Mapping/Selective Renal Denervation Device and SyMapCath Catheter IIDevice

    Radiofrequency ablation of renal arterial sympathetic nerves

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in daytime ASBPTime frame: From baseline to 2 months after RDN

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.